Host: Mario R. Nacinovich, Jr., MSc

Guest: Inderpal Randhawa, MD

What is the connection between allergies and asthma? And, why is allergy testing important in symptomatic patients? Host Mario R. Nacinovich Jr., MSc, Managing Partner at AXON Communications, welcomes Dr. Inderpal Randhawa, Associate Clinical Professor of Pediatrics, UC Irvine School of Medicine and Associate Clinical Professor of Medicine, UCLA David Geffen School of Medicine. In this expert interview sponsored by Quest Diagnostics, Dr. Randhawa will discuss the burden of asthma in the U.S., the challenge of adequately controlling asthma symptoms, the association between asthma and allergy or allergic triggers, and the use of NIH-approved IgE tests to diagnose allergen triggers.

Host: Andrea J. Singer, MD, FACP, CCD

Guest: Steven R. Goldstein, MD

Recent advances in technology are significantly changing the way physicians evaluate patients with abnormal uterine bleeding (AUB). Clinicians must understand the gravity of abnormal uterine bleeding in terms of patient health. One-third of patient visits to the gynecologist are for abnormal bleeding - accounting for more than 70% of gynecologic consults in perimenopausal and postmenopausal women. For younger women between ages 19 and 39, abnormal bleeding most frequently occurs as a result of pregnancy, benign structural lesions, anovulatory cycles in polycystic ovarian syndrome, abnormalities of hormonal contraception, and occasionally even endometrial hyperplasia. Join host Dr. Andrea Singer as she welcomes Dr. Steven R. Goldstein to discuss AUB and Endosee®, an in-office diagnostic hysteroscopy. Dr. Goldstein is a Professor of Obstetrics and Gynecology at the New York University School of Medicine, immediate Past President of the American Institute of Ultrasound in Medicine, and a clinical practitioner in the Faculty Practice Suites at New York University.

Host: Matt Birnholz, MD

Although human breast milk is the preferred source of nutrition for infants and is recommended by the American Academy of Pediatrics to be the exclusive source of nutrition for infants for the first 6 months of life, a number of studies have found that by 3 months of age, nearly half of all infants are receiving at least some infant formula. Several experts have ascribed this discrepancy between recommendations and reality, in part, to the changing landscape of today's work force and the logistical challenges involved in maintaining infants exclusively on breast milk. What factors should guide our care recommendations to parents, and what do we need to know about infant formulas to make better decisions? Listen in to a discussion with leading experts Dr. Frank Greer, neonatologist and Professor Emeritus of Pediatrics at the Wisconsin Perinatal Center at Meriter Hospital in Madison, Wisconsin; Dr. Jenifer R. Lightdale, Division Chief of Pediatric Gastroenterology, Hepatology and Nutrition, Professor of Pediatrics at the University of Massachusetts Medical School; and, Dr. Anthony Kovatch, who is a practicing pediatrician in Pittsburgh, currently working at Pediatric Alliance and recipient of a Patients' Choice Award.

Guest: Anthony J. Cannon, MD

Type 2 diabetes is an epidemic in the United States, affecting nearly 1 in 10 Americans and continuing to rise in both incidence and prevalence nationwide. Join host S. Monet Sifford-Wilson, MD, Senior Medical Director for Novo Nordisk, and her guest Anthony J. Cannon, MD, a clinical endocrinologist in private practice, as they discuss this important issue. Key topics of this program include: Trends in type 2 diabetes epidemiology, treatments, and glycemic control in the United States Advances in the understanding of the pathophysiology of type 2 diabetes Key principles guiding current treatment algorithms © 2015 Novo Nordisk All rights reserved. 1115-00028957-1 December 2015

Host: John P. Troup, PhD

Guest: Tasneem "Taz" Bhatia, MD

What are the major patient concerns and considerations during the menopausal transition years that practitioners should be aware of? Join Metagenics Chief Scientific Officer, John P. Troup, PhD and Dr. Tasneem “Taz” Bhatia as they discuss the quality-of-life issues faced by female patients entering the next stage of life. Learn about the challenges many women face as early as perimenopause, including hot flashes, night sweats, and sleep disturbances. This segment was recorded live at the Anti-Aging Meeting in Las Vegas - their 23rd World Congress in Las Vegas, Nevada. This program is sponsored by the Metagenics Healthcare Institute for Clinical Nutrition, designed for all healthcare providers with roots in integrative, traditional, and functional medicine, seeking to optimize patient outcomes with support from clinical nutrition and lifestyle medicine. Please visit www.mhicn.com for more information.

Host: John P. Troup, PhD

Guest: Jay Lombard, DO

Recorded at the 23rd Annual A4M Conference in Las Vegas, Nevada, John Troup, PhD welcomes Jay Lombard, DO, Founder and Chief Medical Officer of Genomind. They will discuss the role of integrative medicine in managing common neurological conditions that are steadily increasing in prevalence. This program is sponsored by the Metagenics Healthcare Institute for Clinical Nutrition, designed for all healthcare providers with roots in integrative, traditional, and functional medicine, seeking to optimize patient outcomes with support from clinical nutrition and lifestyle medicine. Please visit www.mhicn.com for more information.

Host: Barnett Mennen, MD

Guest: Scott Kaatz, DO, MSc, FACP

Dr. Scott Kaatz joins host Dr. Barry Mennen to discuss SAVAYSA® (edoxaban), as a treatment that reduces the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation and for the treatment of deep vein thrombosis and pulmonary embolism following 5 to 10 days of initial parenteral anticoagulation therapy. SAVAYSA is not indicated for the treatment of patients with nonvalvular atrial fibrillation with creatinine clearance >95 mL/min due to the increased risk of ischemic stroke compared to warfarin.Dr. Kaatz will provide an overview of the key features of SAVAYSA®, key results from the Hokusai VTE trial; and dosing, administration, and highlights of the key safety information.Dr. Barry Mennen and Dr.Scott Kaatz are presenting on behalf of and receiving compensation from Daiichi Sankyo. Inc. The information presented is consistent with FDA guidelines and the program is not CME accredited and may not be used for CME accreditation. This program is intended for healthcare professionals only.

Host: Matt Birnholz, MD

Guest: Alan K. Jacobson, MD, FACC

Dr. Alan Jacobson joins host Dr. Matt Birnholz to discuss SAVAYSA® (edoxaban), as a treatment that reduces the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation and for the treatment of deep vein thrombosis and pulmonary embolism following 5 to 10 days of initial parenteral anticoagulation therapy. SAVAYSA is not indicated for the treatment of patients with nonvalvular atrial fibrillation with creatinine clearance >95 mL/min due to the increased risk of ischemic stroke compared to warfarin.Dr. Matt Birnholz and Dr.Alan Jacobson are presenting on behalf of and receiving compensation from Daiichi Sankyo. Inc. The information presented is consistent with FDA guidelines and the program is not CME accredited and may not be used for CME accreditation. This program is intended for healthcare professionals only.

Host: Matt Birnholz, MD

Guest: Douglas S. Rabin, MD

Guest: Jean Lea Spitz, MPH, CAE, RDMS

Rapid advances are underway in noninvasive prenatal screening to identify fetal abnormalities, leading to the increasing need for updated clinical education at the point of care. To close the informational gaps, a new campaign, led by the Perinatal Quality Foundation with support from Quest Diagnostics, is launching to address educational priorities about advanced prenatal tests. Host Dr. Matt Birnholz welcomes guests Dr. Douglas Rabin, Medical Director of Women’s Health and Medical Affairs with Quest Diagnostics, and Jean Lea Spitz, MPH, CAE, RDMS, Executive Director for The Perinatal Quality Foundation. Their discussion focuses on the goals of this campaign, what clinicians need to know about it, and how it will improve understandings of genetic screening technologies.

Host: Matt Birnholz, MD

Guest: William Short, MD

Since the discovery of HIV more than 3 decades ago, there has been progress in the treatment of the disease. However, there remains a significant need to continue providing adults living with HIV and their physicians with treatment options. The last few years have seen the development of additional treatment options, including fixed-dose combination therapies. Dr. William Short, Associate Professor at Perelman School of Medicine at the University of Pennsylvania in Philadelphia, joins Dr. Matt Birnholz to discuss the considerations in treatment options for adults living with HIV-1, highlighting PREZCOBIX® (darunavir 800 mg/cobicistat 150 mg), one of the treatments in the space. Download and listen today. For more information on PREZCOBIX®, please visit www.PREZCOBIX.com/hcp. This promotional program is sponsored by Janssen Therapeutics, Division of Janssen Products, LP.